Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Cardiovascular Drugs
Erschienen in: American Journal of Cardiovascular Drugs 1/2012

01.02.2012 | Adis Drug Clinical Q&A

Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia

verfasst von: Katherine A. Lyseng-Williamson

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Ezetimibe/simvastatin therapy combines two lipid-lowering compounds with complementary mechanisms of action, thereby blocking the two sources of plasma cholesterol and improving lipid profiles. Ezetimibe/simvastatin is an effective and generally well tolerated adjunct to dietary therapy for markedly reducing lowdensity lipoprotein cholesterol (LDL-C) levels and improving other lipid parameters across diverse patient populations. Dual treatment with ezetimibe/simvastatin is more effective than monotherapy with an HMG-CoA reductase inhibitor (statin), and the addition of ezetimibe to current statin therapy is more effective than doubling the statin dose.
Literatur
1.
National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002 Dec 17. 106 (25): 3143–421.
2.
The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769–818.CrossRef
3.
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl. 2: S1–113.CrossRef
4.
Marques da Silva P, Massano Cardoso S, DYSIS Portugal Investigators. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipdemia International Study (DYSIS). Rev Port Cardiol 2011; 30(1): 47–63.PubMed
5.
Drexel H, Chazelle F, Fauer C, et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events: results of the dyslipidemia international study (DYSIS). Wien Klin Wochenschr 2011 Oct; 123(19–20): 611–617.PubMedCrossRef
6.
González-Juanatey JR, Millán J, Alegría E, et al. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain: DYSIS-Spain Study [in Spanish]. Rev Esp Cardiol 2011 Apr. 64 (4): 286–94.PubMedCrossRef
7.
Horgan S, Crowley J, Feely J, et al. Prevalence of dyslipidaemia in statintreated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS). Ir J Med Sci 2011 Jun. 180 (2): 343–9.PubMedCrossRef
8.
Gitt AK, Jünger C, Smolka W, et al. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol 2010 Nov. 99 (11): 723–33.PubMedCrossRef
9.
Strang AC, Kaasjager HA, Basart DC, et al. Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands: part of the dyslipidaemia international survey. Neth J Med 2010 Apr. 68 (4): 168–74.PubMed
10.
Goodman SG, Langer A, Bastien NR, et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010 Nov; 26(9): e330–5.PubMedCrossRef
11.
Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011 Nov. 28 (11): 1343–51.PubMedCrossRef
12.
Musunuru K, Blumenthal RS. The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles. Clin Cardiol 2008 Jun. 31 (6): 288–90.PubMedCrossRef
13.
Khanderia U, Regal RE, Rubenfire M, et al. The ezetimibe controversy: implications for clinical practice. Ther Adv Cardiovasc Dis 2011 Aug. 5 (4): 199–208.PubMedCrossRef
14.
Vytorin tablets: summary of product characteristics [in Portuguese]. Trofa, Portugal: BIAL-Portela & Co., SA, 2011 Apr 11.
15.
Goltor tablets: summary of product characteristics [in Italian]. Rome: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., 2011.
16.
Inegy tablets: UK summary of product characteristics. Hoddesdon; MSD-SP Ltd, 2011 Jul 28.
17.
Vytorin (ezetimibe/simvastatin) tablets: US prescribing information. North Wales (PA): Merck/Schering-Plough Pharmaceuticals, 2011 Jun.
18.
Kamat SA, Bullano MF, Chang CL, et al. Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Curr Med Res Opin 2011 May. 27 (5): 961–8.PubMedCrossRef
19.
Jia L, Betters JL, Yu Li. Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physio 2011 Mar 17. 73: 239–59.CrossRef
20.
Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002 Dec 18. 40 (12): 2125–34.PubMedCrossRef
21.
Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clinic Proc 2004; 79: 620–9.CrossRef
22.
Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 Nov. 6 (11): 1758–73.CrossRef
23.
Feldman T, Koren M, Insull Jr W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93 (12): 1481–6.PubMedCrossRef
24.
Masana L, Mata P, Gagné C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebocontrolled, 48-week extension study. Clin Ther 2005 Feb. 27 (2): 174–84.PubMedCrossRef
25.
Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab 2011 Jul. 13 (7): 615–28.
26.
Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004 Jun 15. 93 (12): 1487–94.PubMedCrossRef
27.
Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy: the IN-CROSS study. Int J Clin Pract 2009 Apr; 63(4): 547–559.PubMedCrossRef
28.
Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011 Jun. 27 (6): 1191–210.PubMedCrossRef
29.
Averna M, Zaninelli A, Le Grazie C, et al. Ezetimibe/simvastatin 10/20mg versus simvastatin 40mg in coronary heart disease patients. J Clin Lipidol 2010 Jul–Aug; 4(4):272–8.PubMedCrossRef
30.
Gaudiani L, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005 Jan. 7 (1): 88–97.PubMedCrossRef
31.
Bardini G, Giorda CB, Pontiroli AE, et al. Ezetimibe+simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol 2010 May 21; 9: 20.PubMedCrossRef
32.
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011 Jun 25. 377 (9784): 2181–92.PubMedCrossRef
33.
Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or with ezetimibe in familial hypercholesterolemia. N Eng J Med 2008 Apr 3. 358 (14): 1431–43.CrossRef
34.
Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009 Jul. 49 (7): 838–47.PubMedCrossRef
35.
Avellone G, Di Garbo V, Guarnotta V, et al. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Int Angiol 2010 Dec. 29 (6): 514–24.PubMed
36.
Simon A, Gariepy J, Chironi G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002 Feb. 20 (2): 159–69.PubMedCrossRef
37.
Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 2011 Mar. 27 (3): 685–92.PubMedCrossRef
38.
Winkler K, Jacob S, Müller-Schewe T, et al. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis. Epub 2011 Nov 9.
39.
Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 Sep 25. 359 (13): 1343–56.PubMedCrossRef
40.
Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008 Nov. 156 (5): 826–32.PubMedCrossRef
41.
McCormack T, Harvey P, Gaunt R, et al. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010 Jul. 64 (8): 1052–61.PubMedCrossRef
42.
Friedman HS, Rajagopalan S, Barnes JP, et al. Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting. Clin Ther 2011 Feb. 33 (2): 212–24.PubMedCrossRef
43.
Lee YH, Kim MJ, Choi CI, et al. Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults. Arch Pharm Res 2011 Aug. 34 (8): 1331–7.PubMedCrossRef
44.
Furman A, Meier JL, Malmstrom RA, et al. Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. Am J Manag Care 2011; 17 (8): 538–44.PubMed
45.
Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008 Jun 1. 101 (11): 1606–13.PubMedCrossRef
46.
Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008 Sep 25. 359 (13): 1357–66.PubMedCrossRef
Metadaten
Titel
Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia
verfasst von
Katherine A. Lyseng-Williamson
Publikationsdatum
01.02.2012
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 1/2012
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.2165/11209150-000000000-00000

Weitere Artikel der Ausgabe 1/2012

American Journal of Cardiovascular Drugs 1/2012 Zur Ausgabe

Original Research Article

Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension

Review Article

Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus

Review Article

Managing Arrhythmias before and after Aortic Valve Surgery in Children

Current Opinion

Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes

Adis Drug Evaluation

Rivaroxaban

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

13.05.2024 Chronische Herzinsuffizienz Nachrichten

Die Anlage eines interatrialen Shunts zur Reduktion des linksatrialen Drucks ist ein neuer Therapieansatz bei Herzinsuffizienz. Viele Patienten sprechen darauf an, andere jedoch nicht. 

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise